Emergency Department Triage of Patients With Acute Chest Pain Based on the ESC 0/1-hour Algorithm (PRESC1SE-MI)
Launched by UNIVERSITY HOSPITAL, BASEL, SWITZERLAND · Dec 5, 2022
Trial Information
Current as of January 17, 2025
Recruiting
Keywords
ClinConnect Summary
The PRESC1SE-MI study is looking at how to quickly and accurately evaluate patients who arrive at the emergency department with chest pain that might be a heart attack. It compares two methods for testing levels of a heart protein called troponin, which helps doctors understand if there has been damage to the heart. The first method tests troponin levels at the time of admission and again after three hours, while the newer method tests at admission and again after just one hour. This study will help determine if the faster method is just as safe and effective as the traditional one.
To participate in this trial, you need to be at least 18 years old and experiencing chest pain that isn’t the result of an injury, with a suspicion of a heart attack. However, people with severe kidney problems, who have had a cardiac arrest, or who are in a serious condition called cardiogenic shock cannot take part. If eligible, participants will have their blood tested for troponin levels at the specified times, allowing researchers to see how well the quicker method works in real-life situations. This could eventually lead to faster diagnoses and treatment for heart attacks in the emergency department.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients aged 18 and above
- • Presentation with acute non-traumatic acute chest pain to the emergency department
- • Suspicion of acute myocardial infarction
- Exclusion Criteria:
- • Terminal kidney failure requiring dialysis
- • Cardiac arrest
- • Cardiogenic shock
Trial Officials
Christian Müller, MD Prof.
Principal Investigator
University Hospital, Basel, Switzerland
Jasper Boeddinghaus, MD
Principal Investigator
University Hospital, Basel, Switzerland
About University Hospital, Basel, Switzerland
The University Hospital Basel, Switzerland, is a leading academic medical center renowned for its commitment to cutting-edge research and innovative patient care. As a prominent clinical trial sponsor, the hospital leverages its extensive expertise and state-of-the-art facilities to advance medical knowledge and therapeutic options across various disciplines. With a collaborative approach that integrates clinical practice and scientific inquiry, the University Hospital Basel fosters an environment conducive to rigorous clinical trials, ensuring the highest standards of safety and efficacy. Its strategic focus on patient-centered research aims to translate scientific discoveries into tangible health solutions, benefiting both local and global communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Barcelona, , Spain
Leicester, , United Kingdom
Aarau, , Switzerland
Aarau, Aargau, Switzerland
London, , United Kingdom
Luzern, , Switzerland
Seoul, , Korea, Republic Of
Basel, , Switzerland
Valencia, , Spain
Houston, Texas, United States
Zürich, , Switzerland
Roma, , Italy
Madrid, , Spain
Brisbane, , Australia
Wien, , Austria
Helsinki, , Finland
Athens, , Greece
Florence, , Italy
Torino, , Italy
Bucharest, , Romania
Madrid, , Spain
Truro, , United Kingdom
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials